Abstract: PO1855
TMEM27 Expression and Clinical Characteristics and Survival in Clear Cell Renal Cell Carcinoma
Session Information
- Cancer and Kidney Diseases: Nephrotoxins, RCC, and More
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Onco-Nephrology
- 1500 Onco-Nephrology
Authors
- Grewal, Rickinder, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
- Choung, Hae Yoon Grace, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
- Roberts, Lisa Lembeck, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
- Beane, Timothy Jason, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
- Chen, Luojing, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
- Gilroy, Daniel X., Rochester Institute of Technology, Rochester, New York, United States
- Le, Thu H., University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
Background
Transmembrane protein 27 (TMEM27/collectrin), a glycoprotein and homolog of angiotensin-converting enzyme 2 (ACE2), is a regulator of renal amino acid uptake in the proximal tubule and may have a protective role in hypertension. Two previous reports have shown that the absence of TMEM27 expression in clear cell renal cell carcinoma (ccRCC) correlates with poorer cancer-related survival. Here we report our findings of TMEM27 expression in ccRCC and clinical outcomes.
Methods
We conducted a retrospective analysis to identify all cases of ccRCC diagnosed between 2010 and 2015 at the University of Rochester Medical Center. The intensity of TMEM27 immunostaining on tumor tissue was semi-quantitatively graded on a scale of 0, 0.5, 1, 1.5, 2, 2.5, and 3 by a single pathologist, and correlated with tumor characteristics and survival.
Results
There were 321 cases of ccRCC. There was evidence of metastasis at time of nephrectomy in 36 (11.2%), and at the latest follow up in 70 (21.8%), and 82 (25.5%) died as of Spring 2021. TMEM27 staining intensity correlated inversely with various tumor characteristics (Table 1). Kaplan-Meier survival analysis showed worse all-cause mortality for tumors without any TMEM27 staining (0) compared to 0.5 or higher, p = 0.02 by log-rank test.
Conclusion
The absence of TMEM27 expression is associated with more aggressive tumor characteristics and poorer all-cause mortality in ccRCC. TMEM27 may be a useful biomarker to assess cancer prognosis. Further studies are needed to better assess if TMEM27 is protective in RCC.
Table 1: Correlation between TMEM27 Staining and Clinical Characteristics
| Clinical Characteristic | r value | p-value |
| Tumor size | -0.191 | <0.001 |
| TNM stage (pTx) | -0.145 | <0.01 |
| TNM stage (Nx) | -0.152 | NS |
| Furhman grade | -0.187 | <0.001 |
| Sarcomatoid rhabdoid present | -0.073 | NS |
| Large vessel venous invasion | -0.113 | <0.05 |
| Lymphatic invasion | -0.072 | NS |
| Metastasis at time of nephrectomy | -0.126 | <0.05 |
| Metastasis at follow-up | -0.094 | NS |
| Composite | -0.201 | <0.001 |
| Composite with death | -0.202 | <0.001 |
NS: Not Significant, TNM: Tumor, Node, Metastasis